Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company focused on precision oncology that completed its public market debut in 2021 through a business combination with BCTG Acquisition Corp., a blank-check vehicle sponsored by Boxer Capital and TCG Crossover Investors. The company develops targeted cancer therapies via a synthetic lethality platform designed to exploit tumor suppressor gene loss. On August 7, 2026, Tango submitted an amended current report on Form 8-K/A to the SEC, updating disclosures contained in a prior filing. As a post-merger SPAC company, TNGX continues to operate within the oncology segment of the biopharmaceutical sector. Sign up at SpacDesk for complete filing history and analytics on TNGX and the broader SPAC universe.